Analyst Ratings For NASDAQ:BMRN – BioMarin Pharmaceutical (NASDAQ:BMRN)
Today, Morgan Stanley raised its price target on NASDAQ:BMRN – BioMarin Pharmaceutical (NASDAQ:BMRN) to $113.00 per share.
Some recent analyst ratings include
- 4/30/2018-Wedbush Reiterated Rating of Outperform.
- 4/30/2018-Sanford C. Bernstein Reiterated Rating of Market Perform.
- 3/29/2018-Credit Suisse Group Reiterated Rating of Buy.
- 2/27/2018-Royal Bank of Canada Reiterated Rating of Hold.
- On 4/24/2018 Jean Jacques Bienaime, CEO, sold 20,000 with an average share price of $82.43 per share and the total transaction amounting to $1,648,600.00.
- On 4/23/2018 Daniel K Spiegelman, CFO, sold 11,059 with an average share price of $82.15 per share and the total transaction amounting to $908,496.85.
- On 4/20/2018 Jean Jacques Bienaime, CEO, sold 10,000 with an average share price of $83.65 per share and the total transaction amounting to $836,500.00.
- On 4/17/2018 V Bryan Lawlis, Director, sold 3,750 with an average share price of $85.00 per share and the total transaction amounting to $318,750.00.
- On 4/2/2018 Henry J Fuchs, Insider, sold 10,000 with an average share price of $80.12 per share and the total transaction amounting to $801,200.00.
- On 4/2/2018 Jeffrey Robert Ajer, EVP, sold 2,119 with an average share price of $80.12 per share and the total transaction amounting to $169,774.28.
- On 3/29/2018 Jeffrey Robert Ajer, EVP, sold 1,537 with an average share price of $79.69 per share and the total transaction amounting to $122,483.53.
Recent Trading Activity for NASDAQ:BMRN – BioMarin Pharmaceutical (NASDAQ:BMRN)
Shares of NASDAQ:BMRN – BioMarin Pharmaceutical closed the previous trading session at with 84.70999908447266 shares trading hands.